JP2019534330A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019534330A5 JP2019534330A5 JP2019545869A JP2019545869A JP2019534330A5 JP 2019534330 A5 JP2019534330 A5 JP 2019534330A5 JP 2019545869 A JP2019545869 A JP 2019545869A JP 2019545869 A JP2019545869 A JP 2019545869A JP 2019534330 A5 JP2019534330 A5 JP 2019534330A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- dosage form
- polyglutamic acid
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022089345A JP7466822B2 (ja) | 2016-11-01 | 2022-06-01 | 亜鉛－γ－ＰＧＡ組成物およびがんを処置するための方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SG10201609131Y | 2016-11-01 | ||
| SG10201609131YA SG10201609131YA (en) | 2016-11-01 | 2016-11-01 | Zinc-pga compositions and methods for treating cancer |
| PCT/SG2017/050545 WO2018084806A1 (en) | 2016-11-01 | 2017-10-31 | ZINC-γ-PGA COMPOSITIONS AND METHODS FOR TREATING CANCER |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022089345A Division JP7466822B2 (ja) | 2016-11-01 | 2022-06-01 | 亜鉛－γ－ＰＧＡ組成物およびがんを処置するための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019534330A JP2019534330A (ja) | 2019-11-28 |
| JP2019534330A5 true JP2019534330A5 (enExample) | 2020-12-10 |
| JP7083835B2 JP7083835B2 (ja) | 2022-06-13 |
Family
ID=60327362
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019545869A Active JP7083835B2 (ja) | 2016-11-01 | 2017-10-31 | 亜鉛－γ－ＰＧＡ組成物およびがんを処置するための方法 |
| JP2022089345A Active JP7466822B2 (ja) | 2016-11-01 | 2022-06-01 | 亜鉛－γ－ＰＧＡ組成物およびがんを処置するための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022089345A Active JP7466822B2 (ja) | 2016-11-01 | 2022-06-01 | 亜鉛－γ－ＰＧＡ組成物およびがんを処置するための方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11944640B2 (enExample) |
| EP (1) | EP3534914B1 (enExample) |
| JP (2) | JP7083835B2 (enExample) |
| KR (1) | KR102616690B1 (enExample) |
| CN (2) | CN108014131B (enExample) |
| AU (2) | AU2017354787B2 (enExample) |
| CA (1) | CA3042383A1 (enExample) |
| MX (2) | MX395613B (enExample) |
| SG (3) | SG10201609131YA (enExample) |
| WO (1) | WO2018084806A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201609131YA (en) | 2016-11-01 | 2018-06-28 | Xylonix Ip Holdings Pte Ltd | Zinc-pga compositions and methods for treating cancer |
| SG10201708886RA (en) * | 2017-10-30 | 2019-05-30 | Xylonix Ip Holdings Pte Ltd | α-PGA-ZINC COMPOSITIONS AND METHODS FOR TREATING CANCER |
| MX2020013883A (es) * | 2018-06-22 | 2021-05-27 | Xylonix Ip Holdings Pte Ltd | Tratamientos oncológicos con agentes de zinc. |
| KR102094182B1 (ko) * | 2018-06-28 | 2020-03-30 | 주식회사 알랙스탠드 | 아연 함유 수용성 폴리글루타믹산 복합체 조성물 |
| US20220401573A1 (en) * | 2019-12-27 | 2022-12-22 | Wuhan Vast Conduct Science Foundation Co., Ltd. | Composition and method for treatment of multiple sclerosis |
| KR20230158059A (ko) | 2021-03-18 | 2023-11-17 | 자일로닉스 피티이. 엘티디 | 약학적 중합체 접합체 |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2897122A (en) | 1956-10-04 | 1959-07-28 | Frosst & Co Charles E | Enteric coated product |
| JP2712583B2 (ja) | 1989-06-28 | 1998-02-16 | 味の素株式会社 | 易吸収性ミネラル含有飲食物 |
| JP3551149B2 (ja) | 1992-03-24 | 2004-08-04 | 味の素株式会社 | 易吸収性ミネラル含有組成物及びそれを含有する飲食品 |
| US5447732A (en) | 1992-11-25 | 1995-09-05 | Ajinomoto Co., Inc. | High-absorption mineral-containing composition and foods |
| DE69330595T2 (de) | 1992-11-25 | 2002-05-23 | Ajinomoto Co., Inc. | Zubereitungen und Nahrungsmittel enthaltend Mineralien und Poly-gamma-Glutaminsäure |
| IL115156A (en) | 1994-09-06 | 2000-07-16 | Univ Georgia | Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines |
| IT1275923B1 (it) | 1995-03-16 | 1997-10-24 | Valpharma Sa | Formulazioni gastroresistenti contenenti zinco |
| US6441025B2 (en) | 1996-03-12 | 2002-08-27 | Pg-Txl Company, L.P. | Water soluble paclitaxel derivatives |
| JPH11313618A (ja) | 1998-05-06 | 1999-11-16 | Yoshio Inoue | 胃にやさしい家畜用ミネラル（亜鉛）製剤及びその製造法 |
| AU2291001A (en) | 1999-12-23 | 2001-07-03 | Emory University | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states |
| US20020061599A1 (en) | 1999-12-30 | 2002-05-23 | Elling Christian E. | Method of identifying ligands of biological target molecules |
| AU2003232884A1 (en) | 2002-01-25 | 2003-09-02 | Emory University | Solenopsin a, b and analogs as novel angiogenesis inhibitors |
| WO2004080210A1 (en) | 2003-03-14 | 2004-09-23 | Boehringer Ingelheim Danmark A/S | Compositions of dietary metals for support of the physiological intestinal development and prevention of diarrhoea |
| KR100498812B1 (ko) | 2003-07-10 | 2005-07-01 | 주식회사 바이오리더스 | 초고분자량의 폴리감마글루탐산을 함유하는 미네랄의 체내흡수 촉진용 조성물 |
| JP4457641B2 (ja) | 2003-11-10 | 2010-04-28 | 味の素株式会社 | ゼラチンカプセル |
| JP5162812B2 (ja) | 2004-07-08 | 2013-03-13 | 大正製薬株式会社 | 亜鉛含有経口投与用組成物 |
| NZ563686A (en) | 2005-06-07 | 2011-07-29 | Univ Yale | Methods of treating cancer and other conditions or disease states using LFMAU and LDT |
| US20070015814A1 (en) * | 2005-06-10 | 2007-01-18 | Ernest Kun | Parp Modulators and Treatment of Cancer |
| WO2007043606A1 (ja) | 2005-10-12 | 2007-04-19 | Genolac Bl Corporation | アニオン性ポリアミノ酸／金属複合体からなる抗糖尿病薬剤 |
| WO2007109290A2 (en) | 2006-03-20 | 2007-09-27 | Pharmacyclics, Inc. | Water-soluble zinc ionophores, zinc chelators, and/or zinc complexes and use for treating cancer |
| CN104800856A (zh) | 2007-04-10 | 2015-07-29 | 日东电工株式会社 | 多功能聚谷氨酸盐药物载体 |
| WO2008141110A2 (en) | 2007-05-09 | 2008-11-20 | Nitto Denko Corporation | Polyglutamate conjugates and polyglutamate-amino acid conjugates having a plurality of drugs |
| JP2010526812A (ja) | 2007-05-09 | 2010-08-05 | サルトリア・フアーマシユーテイカルズ・エル・エル・シー | 炎症性疾患の治療のためのスピロ化合物 |
| AU2009344184B2 (en) | 2009-04-10 | 2016-05-12 | Cypress Pharmaceuticals, Inc. | Phosphate-binding magnesium salts and uses thereof |
| JO3635B1 (ar) | 2009-05-18 | 2020-08-27 | Millennium Pharm Inc | مركبات صيدلانية صلبة وطرق لانتاجها |
| CN101716180B (zh) | 2009-11-06 | 2013-04-24 | 广西强寿药业集团有限公司 | 一种组合补充锌、钙药物及其制备方法 |
| US20110117210A1 (en) | 2009-11-17 | 2011-05-19 | Andrey Ugolkov | Therapeutic treatment of human cancers using simple salts of zinc |
| WO2011110930A2 (en) | 2010-03-10 | 2011-09-15 | Lupin Limited | Rifaximin ready-to-use suspension |
| UA110853C2 (uk) | 2011-09-13 | 2016-02-25 | Фармасайклікс, Інк. | Лікарські форми інгібітора гістондеацетилази у комбінації з бендамустином та їхнє застосування |
| ES2646927T3 (es) | 2012-11-21 | 2017-12-18 | KBS Research, LLC | Suplementos herbales y métodos de uso de los mismos |
| TWI660748B (zh) | 2013-03-01 | 2019-06-01 | 日商大塚製藥股份有限公司 | 用於口服投藥之包含非晶型托伐普坦（Ｔｏｌｖａｐｔａｎ）的懸浮液 |
| EP2978423A4 (en) | 2013-03-28 | 2016-08-24 | Bbs Nanotechnology Ltd | STABLE NANO COMPOSITION WITH DOXORUBICIN, PROCESS FOR THE PREPARATION THEREOF, THE USE THEREOF AND PHARMACEUTICAL COMPOSITIONS THEREWITH |
| CA2909349C (en) * | 2013-04-12 | 2023-01-03 | Rebecca Lambert Bent | Use of a multi-agent composition for treatment of cancer |
| JP6262334B2 (ja) | 2013-04-26 | 2018-01-17 | 日東電工株式会社 | ポリ（グルタミル−グルタマート）結合体を製造するための大規模な方法 |
| WO2015009699A1 (en) | 2013-07-15 | 2015-01-22 | Ketter Patrick | Methods and compositions to prevent or treat bacterial infections |
| JP2016069303A (ja) | 2014-09-29 | 2016-05-09 | タカラバイオ株式会社 | フコイダンを有効成分とする脱毛抑制用組成物 |
| DK3006045T3 (en) | 2014-10-07 | 2017-07-17 | Cyprumed Gmbh | Pharmaceutical formulations for oral administration of peptide or protein drugs |
| ES2806426T3 (es) | 2014-10-08 | 2021-02-17 | Synthetic Biologics Inc | Formulaciones de betalactamasas y usos de las mismas |
| US20160122739A1 (en) | 2014-10-31 | 2016-05-05 | Wisconsin Alumni Research Foundation | Factor ix variants and methods of use therefor |
| JP6716464B2 (ja) | 2014-12-03 | 2020-07-01 | ノーベルファーマ株式会社 | 酢酸亜鉛水和物錠及びその製造方法 |
| MX2019002023A (es) | 2016-08-19 | 2019-11-18 | Brooklyn Immunotherapeutics Llc | Usos de inhibidores de pd-1/pd-l1 y/o inhibidores de ctla-4 con un producto biológico que contiene múltiples componentes citocínicos para tratar el cáncer. |
| SG10201609131YA (en) | 2016-11-01 | 2018-06-28 | Xylonix Ip Holdings Pte Ltd | Zinc-pga compositions and methods for treating cancer |
| SG10201708886RA (en) | 2017-10-30 | 2019-05-30 | Xylonix Ip Holdings Pte Ltd | α-PGA-ZINC COMPOSITIONS AND METHODS FOR TREATING CANCER |
| MX2020013883A (es) | 2018-06-22 | 2021-05-27 | Xylonix Ip Holdings Pte Ltd | Tratamientos oncológicos con agentes de zinc. |
-
2016
- 2016-11-01 SG SG10201609131YA patent/SG10201609131YA/en unknown
-
2017
- 2017-10-31 AU AU2017354787A patent/AU2017354787B2/en active Active
- 2017-10-31 KR KR1020197015744A patent/KR102616690B1/ko active Active
- 2017-10-31 MX MX2019005104A patent/MX395613B/es unknown
- 2017-10-31 EP EP17798014.1A patent/EP3534914B1/en active Active
- 2017-10-31 CA CA3042383A patent/CA3042383A1/en active Pending
- 2017-10-31 WO PCT/SG2017/050545 patent/WO2018084806A1/en not_active Ceased
- 2017-10-31 SG SG10202013112YA patent/SG10202013112YA/en unknown
- 2017-10-31 US US16/346,286 patent/US11944640B2/en active Active
- 2017-10-31 JP JP2019545869A patent/JP7083835B2/ja active Active
- 2017-10-31 SG SG11201903753QA patent/SG11201903753QA/en unknown
- 2017-11-01 CN CN201711108631.5A patent/CN108014131B/zh active Active
- 2017-11-01 CN CN202310311382.9A patent/CN116350658A/zh active Pending
-
2019
- 2019-04-30 MX MX2022011372A patent/MX2022011372A/es unknown
-
2022
- 2022-06-01 JP JP2022089345A patent/JP7466822B2/ja active Active
-
2023
- 2023-05-23 AU AU2023203220A patent/AU2023203220B2/en active Active
-
2024
- 2024-04-01 US US18/623,943 patent/US20250025496A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019534330A5 (enExample) | ||
| CN103917231B (zh) | 组蛋白脱乙酰酶抑制剂与苯达莫司汀的联合制剂及其用途 | |
| US20140030323A1 (en) | Controlled release of n-acetylcysteine (nac) for reduction of systemic and/or vascular inflammation | |
| HRP20130961T1 (hr) | Kombinacije za tretman raka | |
| JP2025065389A (ja) | 化合物の製剤およびそれらの使用 | |
| JP2016504384A5 (enExample) | ||
| JP2009215293A5 (enExample) | ||
| JP7466822B2 (ja) | 亜鉛－γ－ＰＧＡ組成物およびがんを処置するための方法 | |
| WO2020239097A1 (zh) | 一种parp抑制剂微丸制剂及其制备工艺 | |
| JP2013527224A5 (enExample) | ||
| JP2016155826A (ja) | 経口薬物療法のための方法および組成物 | |
| TW202214243A (zh) | 西奧羅尼聯合免疫檢查點抑製劑在抗腫瘤治療中的應用 | |
| CN101686944A (zh) | 熊去氧胆酸的高剂量组合物 | |
| JP2008533127A5 (enExample) | ||
| CN105879031A (zh) | 协同治疗肿瘤的非抗癌药组合物 | |
| TWI447113B (zh) | 醫藥組合 | |
| TWI399206B (zh) | 抗腫瘤劑 | |
| JP2021501143A5 (enExample) | ||
| CN103327975A (zh) | 用于治疗多形性成胶质母细胞瘤的含有马西替坦的组合物 | |
| CN106102744A (zh) | 用于治疗异常细胞生长的组合物和方法 | |
| KR20210106477A (ko) | 5-브로모피리딘-3-일 3-데옥시-3-[4-(3,4,5-트리플루오로페닐)-1h-1,2,3-트리아졸-1-일]-1-티오-알파-d-갈락토피라노사이드의 비정질 형태 | |
| RU2016116915A (ru) | Комбинация | |
| EP4331569A1 (en) | Sorafenib or donafenib oral preparation with low dose and high drug exposure, and application thereof | |
| JP7352541B2 (ja) | がんを処置するためのアルファ－ポリグルタミン酸－亜鉛を含む組成物 | |
| PH12022552521A1 (en) | A modified release multiple unit oral dosage form of doxylamine succinate and pyridoxine hydrochloride and a process for its preparation |